Under: Sexual Health
Best Peptides for Female Libido
Addressing low sexual desire in women through hormonal and neurological pathways.
Female sexual dysfunction, characterized by persistent low desire or arousal, involves complex interactions between hormonal regulation, neurotransmitter signaling, and psychological factors. Research peptides like PT-141 (Bremelanotide) are being investigated for their ability to modulate melanocortin receptors in the central nervous system—a mechanism distinct from traditional pharmaceutical approaches—to potentially enhance sexual motivation and arousal independent of hormonal status.
Research protocols for peptides in this area typically employ subcutaneous or intranasal administration, with timing often coordinated around anticipated sexual activity rather than daily dosing schedules. Individual response variability is significant, and protocols in clinical research have generally used conservative dosing approaches with careful monitoring for systemic effects.
Peptides Studied for Female Libido
| Peptide | Evidence | Notes | Actions |
|---|---|---|---|
| PT-141 (Bremelanotide) PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. | high | — | |
| PT-141 (Bremelanotide) PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. | high | — |
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.